Long-term treatment of giant cell tumors of bone (GCTB) with denosumab: a two institutions 8-year experience
| Autor: | Imran S. Syed, Prarthana Parthasarathy, Anna Paioli, Piero Picci, Neal Shiv Chawla, Justin Daneshrad, Sant P. Chawla, William E. Mendanha, Emanuela Palmerini, Stefano Ferrari, Emanuela Marchesi, Kamalesh Kumar Sankhala, Madhuri Sudan, Martina Piccinni Leopardi |
|---|---|
| Přispěvatelé: | Neal Shiv Chawla, Madhuri Sudan, Imran Syed, Sant P. Chawla, Stefano Ferrari, Piero Picci, Emanuela Marchesi, Martina Piccinni Leopardi, Kamalesh Kumar Sankhala, Prarthana Parthasarathy, William Esteves Mendanha, Anna Paioli, Justin Daneshrad, Emanuela Palmerini |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research Pathology medicine.medical_specialty Long term treatment business.industry Giant cell tumours 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Denosumab Oncology 030220 oncology & carcinogenesis medicine Giant Cell Tumors business giant cell tumors of bone Denosumab medicine.drug |
| Zdroj: | Alma Mater Studiorum Università di Bologna-IRIS |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.11021 |
| Popis: | 11021Background: Giant cell tumours of bone (GCTB’s) are RANK-ligand (RANK-L) positive, aggressive and progressive osteolytic tumors. Denosumab, a RANK-L inhibitor, was FDA-approved for adults and ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|